Idorsia

At the AHA congress, Idorsia presented further analyses from the Phase III Precision study showing rapid double-digit blood-pressure reductions in two hard-to-treat hypertension patient groups (obesity; combined heart, kidney and metabolic diseases). The data also point to a possible kidney-protective effect. Aprocitentan is approved in the US as Tryvio and in the EU, the UK, Switzerland and Canada as Jeraygo. » More on finanzen.net

Idorsia will present new analysis data on aprocitentan on October 10 at the annual meeting of the American Heart Association. The evaluation of the phase‑3 Precision study involving 730 patients shows that the drug effectively lowers blood pressure in severe hypertension, especially in overweight individuals and in patients with combined heart, kidney and metabolic diseases. Aprocitentan has been approved in the US as Tryvio since October 2024 and is available in the EU, the UK, Switzerland and Canada as Jeraygo. » More on finanzen.net

Idorsia says it is on track to meet its targets after the first half of 2026 and maintains its full-year outlook. Total revenue fell to CHF 110 million, of which Quviviq accounted for CHF 91 million, up 62% year‑on‑year. On an operational US‑GAAP basis the company reported an operating loss of CHF 63 million and a net loss of CHF 152 million; higher finance expenses weighed on results. Cash and cash equivalents amounted to CHF 89 million at the end of June. For 2026 Idorsia expects Quviviq sales of around CHF 200 million and an operational US‑GAAP loss of about CHF 160 million. The company also reports progress with Aprocitentan and other pipeline projects and is negotiating distribution and co‑promotion partnerships. » More on finanzen.net